Background. This study aimed to evaluate the efficacy and safety of low-dose neoadjuvant chemotherapy with an oral fluoropyrimidine containing tegafur, gimeracil, and oteracil (S-1) and oxaliplatin (NAC-SOX) in improving resectability and long-term outcomes in patients with advanced gastric cancer. Methods. This was a single-center, retrospective study analyzing patients with advanced gastric cancer or esophagogastric junction cancer who received NAC-SOX. (S-1: 80–120 mg/m2, oxaliplatin: 100 mg/m2) followed by gastrectomy with D2 lymphadenectomy. Clinical background, chemotherapy-related adverse effects, surgical outcomes, pathological response, and survival were assessed. Results. A total of 34 patients underwent NAC-SOX, with a median age of 74 years. The most common surgical procedure was total gastrectomy (n = 16). Peripheral neuropathy was the most frequent adverse effect, but no grade 4 toxicities were observed. Postoperative complications (≥CD grade 3a) occurred in 8.8% of cases, with no treatment-related deaths. R0 resection was achieved in 85.3% of cases, and the pathological complete response rate was 20.6%. The 3-year recurrence-free and overall survival rates were 71.3% and 83.2%, respectively. Conclusions. Low-dose NAC-SOX demonstrated favorable efficacy and safety, achieving high R0 resection and pathological response rates. Further prospective studies are needed to optimize treatment strategies.
Akai et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: